Judith Shlay
Concepts (244)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sexually Transmitted Diseases | 11 | 2020 | 166 | 2.250 |
Why?
| | Text Messaging | 7 | 2022 | 182 | 2.160 |
Why?
| | School Health Services | 7 | 2015 | 224 | 2.100 |
Why?
| | Sexual Health | 6 | 2022 | 66 | 2.070 |
Why?
| | Immunization Programs | 6 | 2015 | 194 | 1.940 |
Why?
| | Pregnancy in Adolescence | 4 | 2017 | 84 | 1.460 |
Why?
| | Safety-net Providers | 2 | 2020 | 125 | 1.120 |
Why?
| | Opioid-Related Disorders | 3 | 2022 | 600 | 1.100 |
Why?
| | Sexual Behavior | 10 | 2022 | 491 | 0.980 |
Why?
| | Influenza Vaccines | 4 | 2015 | 529 | 0.980 |
Why?
| | Condoms | 5 | 2016 | 101 | 0.970 |
Why?
| | Stereotyping | 1 | 2026 | 47 | 0.940 |
Why?
| | Health Promotion | 4 | 2026 | 774 | 0.930 |
Why?
| | Reimbursement Mechanisms | 3 | 2015 | 80 | 0.900 |
Why?
| | Colorado | 16 | 2026 | 4564 | 0.810 |
Why?
| | Social Stigma | 1 | 2026 | 171 | 0.800 |
Why?
| | Insurance, Health, Reimbursement | 2 | 2014 | 96 | 0.790 |
Why?
| | Language | 1 | 2026 | 321 | 0.760 |
Why?
| | Ambulatory Care Facilities | 5 | 2013 | 265 | 0.760 |
Why?
| | Pregnancy, Unwanted | 3 | 2009 | 15 | 0.710 |
Why?
| | Electronic Health Records | 3 | 2026 | 1173 | 0.690 |
Why?
| | Attitude to Health | 2 | 2014 | 436 | 0.660 |
Why?
| | Body Composition | 7 | 2010 | 706 | 0.660 |
Why?
| | Analgesics, Opioid | 4 | 2022 | 1143 | 0.650 |
Why?
| | Family Planning Services | 2 | 2013 | 94 | 0.650 |
Why?
| | Contraception Behavior | 2 | 2016 | 107 | 0.620 |
Why?
| | Substance-Related Disorders | 2 | 2026 | 1094 | 0.610 |
Why?
| | HIV Infections | 13 | 2026 | 3154 | 0.610 |
Why?
| | Contraception | 5 | 2022 | 169 | 0.580 |
Why?
| | Papillomavirus Infections | 6 | 2013 | 345 | 0.580 |
Why?
| | Patient Participation | 2 | 2019 | 431 | 0.540 |
Why?
| | Influenza, Human | 2 | 2014 | 616 | 0.540 |
Why?
| | Parental Consent | 2 | 2014 | 25 | 0.520 |
Why?
| | Reverse Transcriptase Inhibitors | 2 | 2008 | 87 | 0.520 |
Why?
| | Anti-HIV Agents | 4 | 2009 | 888 | 0.500 |
Why?
| | Opiate Substitution Treatment | 1 | 2019 | 187 | 0.490 |
Why?
| | Sex Education | 1 | 2016 | 34 | 0.480 |
Why?
| | Adolescent | 26 | 2026 | 22428 | 0.480 |
Why?
| | Papanicolaou Test | 4 | 2013 | 35 | 0.470 |
Why?
| | Vaginal Smears | 4 | 2013 | 55 | 0.460 |
Why?
| | Parents | 2 | 2014 | 1403 | 0.450 |
Why?
| | Adolescent Health Services | 1 | 2015 | 75 | 0.430 |
Why?
| | Minority Health | 1 | 2014 | 18 | 0.420 |
Why?
| | Female | 48 | 2026 | 78271 | 0.410 |
Why?
| | Financing, Government | 1 | 2014 | 53 | 0.410 |
Why?
| | Social Values | 1 | 2014 | 40 | 0.410 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2014 | 102 | 0.400 |
Why?
| | Adult | 34 | 2026 | 40449 | 0.390 |
Why?
| | Delivery of Health Care | 3 | 2022 | 947 | 0.380 |
Why?
| | Pregnancy | 15 | 2026 | 7190 | 0.370 |
Why?
| | Health Care Costs | 2 | 2014 | 427 | 0.360 |
Why?
| | Humans | 53 | 2026 | 144759 | 0.360 |
Why?
| | Geographic Information Systems | 1 | 2011 | 46 | 0.350 |
Why?
| | Male | 31 | 2026 | 72315 | 0.340 |
Why?
| | Tumor Virus Infections | 1 | 2011 | 49 | 0.340 |
Why?
| | Stavudine | 2 | 2008 | 6 | 0.340 |
Why?
| | Dideoxynucleosides | 2 | 2008 | 22 | 0.330 |
Why?
| | Lamivudine | 2 | 2008 | 65 | 0.330 |
Why?
| | Subcutaneous Fat | 3 | 2010 | 78 | 0.300 |
Why?
| | Social Support | 1 | 2014 | 652 | 0.300 |
Why?
| | Vaccines | 1 | 2014 | 389 | 0.290 |
Why?
| | Anti-Retroviral Agents | 4 | 2013 | 250 | 0.280 |
Why?
| | Public Health | 1 | 2013 | 566 | 0.270 |
Why?
| | Zidovudine | 1 | 2008 | 77 | 0.270 |
Why?
| | Vaccination | 3 | 2013 | 1423 | 0.270 |
Why?
| | Insurance, Health | 3 | 2015 | 302 | 0.260 |
Why?
| | HIV Protease Inhibitors | 1 | 2007 | 69 | 0.250 |
Why?
| | Costs and Cost Analysis | 2 | 2020 | 219 | 0.250 |
Why?
| | Health Status | 1 | 2011 | 836 | 0.240 |
Why?
| | Program Evaluation | 4 | 2026 | 948 | 0.230 |
Why?
| | Indians, North American | 1 | 2011 | 647 | 0.220 |
Why?
| | Patient Compliance | 1 | 2009 | 588 | 0.220 |
Why?
| | Primary Health Care | 2 | 2014 | 1733 | 0.220 |
Why?
| | Papillomavirus Vaccines | 3 | 2013 | 297 | 0.220 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2026 | 81 | 0.220 |
Why?
| | Natural Language Processing | 1 | 2026 | 103 | 0.220 |
Why?
| | Antiretroviral Therapy, Highly Active | 5 | 2010 | 278 | 0.220 |
Why?
| | Focus Groups | 3 | 2026 | 573 | 0.210 |
Why?
| | Middle Aged | 20 | 2019 | 35875 | 0.210 |
Why?
| | Risk Assessment | 3 | 2013 | 3671 | 0.210 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2026 | 136 | 0.210 |
Why?
| | Attitude of Health Personnel | 1 | 2012 | 1185 | 0.210 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2026 | 428 | 0.210 |
Why?
| | Health Knowledge, Attitudes, Practice | 3 | 2026 | 1414 | 0.210 |
Why?
| | Community-Institutional Relations | 2 | 2015 | 101 | 0.210 |
Why?
| | Physicians | 1 | 2012 | 939 | 0.200 |
Why?
| | Diagnostic Errors | 1 | 2005 | 175 | 0.200 |
Why?
| | HIV-1 | 4 | 2011 | 896 | 0.190 |
Why?
| | Pelvic Inflammatory Disease | 1 | 2022 | 12 | 0.180 |
Why?
| | Follow-Up Studies | 6 | 2017 | 5408 | 0.180 |
Why?
| | Intrauterine Devices | 1 | 2022 | 29 | 0.180 |
Why?
| | Reproductive Health | 1 | 2022 | 91 | 0.180 |
Why?
| | Long-Acting Reversible Contraception | 1 | 2022 | 34 | 0.170 |
Why?
| | Human papillomavirus 16 | 2 | 2011 | 27 | 0.170 |
Why?
| | United States | 9 | 2020 | 15966 | 0.170 |
Why?
| | Patient Acceptance of Health Care | 3 | 2014 | 885 | 0.160 |
Why?
| | Heroin | 1 | 2020 | 29 | 0.150 |
Why?
| | Allied Health Personnel | 1 | 2020 | 55 | 0.150 |
Why?
| | Cardiovascular Diseases | 1 | 2011 | 2168 | 0.150 |
Why?
| | Incidence | 4 | 2013 | 2879 | 0.150 |
Why?
| | Prevalence | 5 | 2013 | 2834 | 0.140 |
Why?
| | Multivariate Analysis | 4 | 2009 | 1539 | 0.140 |
Why?
| | Drug Prescriptions | 1 | 2020 | 284 | 0.140 |
Why?
| | HIV-Associated Lipodystrophy Syndrome | 2 | 2010 | 11 | 0.130 |
Why?
| | Inpatients | 1 | 2022 | 545 | 0.130 |
Why?
| | Lipids | 3 | 2009 | 710 | 0.130 |
Why?
| | Uterine Cervical Neoplasms | 2 | 2013 | 267 | 0.130 |
Why?
| | Young Adult | 6 | 2026 | 14105 | 0.130 |
Why?
| | Cost-Benefit Analysis | 2 | 2013 | 634 | 0.120 |
Why?
| | Adipose Tissue | 4 | 2010 | 652 | 0.120 |
Why?
| | Child | 5 | 2019 | 22633 | 0.120 |
Why?
| | Reminder Systems | 1 | 2017 | 141 | 0.120 |
Why?
| | Medicaid | 1 | 2020 | 461 | 0.120 |
Why?
| | Organizational Case Studies | 1 | 2015 | 69 | 0.110 |
Why?
| | Drug Overdose | 1 | 2020 | 370 | 0.110 |
Why?
| | Women's Health | 2 | 2009 | 310 | 0.110 |
Why?
| | Inflammation | 1 | 2026 | 2878 | 0.110 |
Why?
| | Health Plan Implementation | 1 | 2015 | 136 | 0.100 |
Why?
| | Direct Service Costs | 1 | 2014 | 7 | 0.100 |
Why?
| | Immunization Schedule | 1 | 2015 | 187 | 0.100 |
Why?
| | Machine Learning | 1 | 2020 | 585 | 0.100 |
Why?
| | Cervix Uteri | 2 | 2011 | 50 | 0.100 |
Why?
| | National Health Programs | 1 | 2013 | 23 | 0.100 |
Why?
| | AIDS Dementia Complex | 1 | 2013 | 52 | 0.100 |
Why?
| | Sex Counseling | 2 | 2003 | 4 | 0.100 |
Why?
| | Models, Immunological | 1 | 2013 | 100 | 0.100 |
Why?
| | Research Design | 1 | 2019 | 1135 | 0.100 |
Why?
| | Cross-Sectional Studies | 6 | 2013 | 5868 | 0.090 |
Why?
| | Emergency Medical Services | 1 | 2020 | 696 | 0.090 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 1053 | 0.090 |
Why?
| | Health Services Needs and Demand | 1 | 2014 | 280 | 0.090 |
Why?
| | Mass Screening | 2 | 2013 | 1347 | 0.090 |
Why?
| | Uterine Cervical Dysplasia | 2 | 2011 | 27 | 0.090 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2011 | 37 | 0.090 |
Why?
| | Time Factors | 4 | 2013 | 7173 | 0.090 |
Why?
| | Human papillomavirus 18 | 1 | 2011 | 12 | 0.090 |
Why?
| | Schools | 1 | 2014 | 453 | 0.080 |
Why?
| | Contraceptive Agents, Female | 1 | 2011 | 80 | 0.080 |
Why?
| | Protease Inhibitors | 1 | 2011 | 102 | 0.080 |
Why?
| | Self Efficacy | 1 | 2014 | 414 | 0.080 |
Why?
| | Urban Population | 2 | 2004 | 491 | 0.080 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 529 | 0.080 |
Why?
| | Hospitalization | 1 | 2020 | 2433 | 0.080 |
Why?
| | Long QT Syndrome | 1 | 2011 | 69 | 0.080 |
Why?
| | Regression Analysis | 2 | 2009 | 1003 | 0.080 |
Why?
| | Health Education | 1 | 2013 | 358 | 0.080 |
Why?
| | Risk-Taking | 2 | 2002 | 328 | 0.070 |
Why?
| | Life Style | 1 | 2011 | 479 | 0.070 |
Why?
| | Learning | 1 | 2013 | 452 | 0.070 |
Why?
| | Ambulatory Care | 1 | 2013 | 600 | 0.070 |
Why?
| | Neuropsychological Tests | 1 | 2013 | 1134 | 0.070 |
Why?
| | Pilot Projects | 1 | 2014 | 1886 | 0.070 |
Why?
| | Virology | 1 | 2008 | 36 | 0.070 |
Why?
| | Cohort Studies | 4 | 2008 | 5960 | 0.070 |
Why?
| | Odds Ratio | 1 | 2009 | 1075 | 0.060 |
Why?
| | Osteoporosis | 1 | 2009 | 236 | 0.060 |
Why?
| | Aged | 6 | 2011 | 25913 | 0.060 |
Why?
| | Bone Density | 1 | 2009 | 482 | 0.060 |
Why?
| | Risk Factors | 5 | 2011 | 10779 | 0.060 |
Why?
| | Didanosine | 1 | 2005 | 13 | 0.060 |
Why?
| | Practice Guidelines as Topic | 1 | 2013 | 1560 | 0.060 |
Why?
| | Genital Diseases, Female | 1 | 2005 | 31 | 0.050 |
Why?
| | Socioeconomic Factors | 1 | 2009 | 1326 | 0.050 |
Why?
| | Vaginosis, Bacterial | 1 | 2004 | 10 | 0.050 |
Why?
| | Prospective Studies | 2 | 2009 | 7990 | 0.050 |
Why?
| | Community-Based Participatory Research | 1 | 2026 | 166 | 0.050 |
Why?
| | Urban Health Services | 1 | 2004 | 70 | 0.050 |
Why?
| | Abortion, Therapeutic | 1 | 2003 | 3 | 0.050 |
Why?
| | Spermatocidal Agents | 1 | 2003 | 7 | 0.050 |
Why?
| | CD4 Lymphocyte Count | 3 | 2010 | 277 | 0.050 |
Why?
| | Fetal Blood | 1 | 2026 | 342 | 0.050 |
Why?
| | Pregnancy Rate | 1 | 2003 | 69 | 0.050 |
Why?
| | Catheters, Indwelling | 1 | 2003 | 96 | 0.050 |
Why?
| | Killer Cells, Natural | 1 | 2026 | 467 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2015 | 1720 | 0.050 |
Why?
| | Hysterectomy | 1 | 2003 | 137 | 0.050 |
Why?
| | Dendritic Cells | 1 | 2026 | 499 | 0.050 |
Why?
| | Community Health Centers | 1 | 2002 | 59 | 0.040 |
Why?
| | Program Development | 2 | 2015 | 370 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2009 | 2947 | 0.040 |
Why?
| | Contraceptive Agents | 1 | 2022 | 65 | 0.040 |
Why?
| | Risk | 1 | 2004 | 911 | 0.040 |
Why?
| | Postoperative Care | 1 | 2003 | 288 | 0.040 |
Why?
| | Forecasting | 1 | 2002 | 391 | 0.040 |
Why?
| | Insulin Resistance | 2 | 2009 | 1241 | 0.040 |
Why?
| | Papillomaviridae | 2 | 2013 | 115 | 0.040 |
Why?
| | Blood Glucose | 2 | 2009 | 2327 | 0.040 |
Why?
| | Counseling | 1 | 2003 | 408 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 1985 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2026 | 846 | 0.040 |
Why?
| | Child, Preschool | 1 | 2014 | 11787 | 0.040 |
Why?
| | Logistic Models | 1 | 2004 | 2117 | 0.040 |
Why?
| | Absorptiometry, Photon | 2 | 2010 | 276 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2002 | 1325 | 0.040 |
Why?
| | Insulin | 2 | 2009 | 2507 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2003 | 851 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2002 | 2115 | 0.030 |
Why?
| | Retrospective Studies | 3 | 2022 | 17066 | 0.030 |
Why?
| | Viral Load | 2 | 2011 | 526 | 0.030 |
Why?
| | Electric Impedance | 2 | 2007 | 111 | 0.030 |
Why?
| | Automation | 1 | 2015 | 102 | 0.030 |
Why?
| | Motivation | 1 | 2020 | 610 | 0.030 |
Why?
| | Cell Phone | 1 | 2015 | 82 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2026 | 6429 | 0.030 |
Why?
| | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 1 | 2013 | 13 | 0.020 |
Why?
| | Epidemiological Monitoring | 1 | 2013 | 69 | 0.020 |
Why?
| | Data Collection | 1 | 2015 | 633 | 0.020 |
Why?
| | Infant | 1 | 2026 | 10034 | 0.020 |
Why?
| | Coitus | 1 | 2011 | 23 | 0.020 |
Why?
| | Sentinel Surveillance | 1 | 2011 | 46 | 0.020 |
Why?
| | Sex Factors | 2 | 2008 | 2112 | 0.020 |
Why?
| | Electrocardiography, Ambulatory | 1 | 2011 | 64 | 0.020 |
Why?
| | Subcutaneous Fat, Abdominal | 1 | 2010 | 15 | 0.020 |
Why?
| | Needs Assessment | 1 | 2013 | 404 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 2010 | 112 | 0.020 |
Why?
| | Sexual Partners | 1 | 2011 | 192 | 0.020 |
Why?
| | Health Behavior | 1 | 2015 | 785 | 0.020 |
Why?
| | Hip Joint | 1 | 2009 | 172 | 0.020 |
Why?
| | Adolescent Behavior | 1 | 2013 | 501 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2009 | 779 | 0.020 |
Why?
| | Lumbar Vertebrae | 1 | 2009 | 252 | 0.020 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2008 | 139 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2027 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2008 | 216 | 0.010 |
Why?
| | Anthropometry | 1 | 2005 | 200 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1054 | 0.010 |
Why?
| | Liver Diseases | 1 | 2008 | 304 | 0.010 |
Why?
| | Metronidazole | 1 | 2004 | 20 | 0.010 |
Why?
| | Prognosis | 1 | 2013 | 4282 | 0.010 |
Why?
| | Treatment Outcome | 2 | 2011 | 11679 | 0.010 |
Why?
| | Verbal Behavior | 1 | 2004 | 43 | 0.010 |
Why?
| | Fractures, Bone | 1 | 2009 | 414 | 0.010 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2004 | 193 | 0.010 |
Why?
| | Device Removal | 1 | 2003 | 143 | 0.010 |
Why?
| | Anti-Infective Agents | 1 | 2004 | 242 | 0.010 |
Why?
| | RNA, Viral | 1 | 2005 | 688 | 0.010 |
Why?
| | Recurrence | 1 | 2004 | 1135 | 0.010 |
Why?
| | Evidence-Based Medicine | 1 | 2004 | 732 | 0.010 |
Why?
| | Smoking | 1 | 2007 | 1472 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2013 | 6048 | 0.010 |
Why?
| | Age Factors | 1 | 2007 | 3333 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2009 | 2730 | 0.010 |
Why?
| | Body Mass Index | 1 | 2007 | 2438 | 0.010 |
Why?
| | Pain | 1 | 2003 | 779 | 0.010 |
Why?
|
|
Shlay's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|